S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
CPIX · Cumberland Pharmaceuticals Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Cumberland Pharmaceuticals Inc (CPIX)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$8.30
+0.38
(+4.80%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$8.30
$8.30
$8.66
52-WEEK RANGE
$8.30
$1.85
$9.28
What's happening
- CPIX is up 4.80% today, trading at $8.30. — Live quote
- Volume today (3,483) is well below its 3-month average of 76,040. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 0
Buy 0
Hold 3
Sell 1
Strong sell 2
Aggregate ratings for 2026-09-01 (6 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CPIX
+88.19%
vs S&P 500
+75.33%
1-YEAR RETURN
CPIX
+121.60%
vs S&P 500
+105.38%
6-MONTH RETURN
CPIX
+142.39%
3-MONTH RETURN
CPIX
-3.97%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.20
Est. $—
2026-04-26 (Q1 2026)
$-0.13
Est. $—
2026-01-26 (Q4 2025)
$-0.01
Est. $—
2025-10-26 (Q3 2025)
$-0.06
Est. $—
Valuation Measures & Ratios
Enterprise Value4$107.2M
Forward P/E5—
PEG Ratio6-0.04
Price / Sales (TTM1)3.55
Price / Book75.57
EV4 / Revenue3.43
EV4 / EBITDA86.24
Profit Margin-34.45%
Operating Margin-30.79%
Return on Equity (ROE8)-47.84%
Return on Assets (ROA9)-15.58%
Avg Volume (3M)76,040
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 |
|---|---|---|---|---|---|
| Market cap | $75.5M | $38.1M | $48.3M | $36.3M | $38.1M |
| P/E | -6.92 | -5.16 | -17.02 | -10.90 | -13.00 |
| Price/Book | 4.33 | 1.76 | 1.94 | 1.39 | 1.36 |
| EV/EBITDA | -13.06 | -5.22 | -36.15 | -20.38 | -8.24 |
| ROE | -62.61% | -34.12% | -11.40% | -12.74% | -10.47% |
| ROA | -17.36% | -10.40% | -3.69% | -5.05% | -4.32% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short348,880
Change from Prior Settlement+38.20%
% of Float—
Days to Cover (Short Ratio)7.53
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +121.6%. Finnhub market metrics ↗
- Latest SEC filing is Form 8-K, filed 2026-08-28; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -98.5% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -34.5%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CPIX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $166.5K | — | — | — | $380.8K | — | — | — |
| Operating income | -$3.2M | -$3.1M | -$1.4M | -$2.0M | -$3.1M | $1.3M | -$1.8M | -$1.7M |
| Net income | -$4.3M | -$3.3M | -$1.4M | -$1.9M | -$740.7K | $1.3M | -$1.9M | -$1.5M |
| EPS (diluted) | $-0.29 | $-0.22 | $-0.09 | $-0.13 | $-0.05 | $0.08 | $-0.14 | $-0.11 |
| EPS (basic) | $-0.29 | $-0.22 | $-0.09 | $-0.13 | $-0.05 | $0.08 | $-0.14 | $-0.11 |
| Operating margin | -$1.9K | — | — | — | -$819 | — | — | — |
| Net margin | -$2.6K | — | — | — | -$195 | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $62.9M | $71.0M | $76.8M | $65.9M | $67.9M | $69.9M | $75.6M | $76.7M |
| Total liabilities | $45.8M | $49.7M | $52.3M | $40.1M | $40.2M | $41.6M | $53.0M | $52.3M |
| Stockholders' equity | $17.4M | $21.6M | $24.9M | $26.1M | $28.0M | $28.7M | $22.9M | $24.8M |
| Total current assets | $33.6M | $32.8M | $37.1M | $29.9M | $31.2M | $31.9M | $36.5M | $35.2M |
| Total current liabilities | $35.2M | $34.5M | $36.7M | $24.3M | $24.0M | $25.5M | $31.6M | $31.1M |
| Cash & equivalents | $3.9M | $11.0M | $11.4M | $15.2M | $16.1M | $15.1M | $18.0M | $17.5M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | $13.4M | $14.3M | $16.9M | $10.4M | $10.3M | $10.5M | $11.7M | $11.3M |
| Inventory | $29.9K | $5.5M | $29.9K | $2.9M | $3.2M | $4.1M | $4.0M | $4.5M |
| Other current assets | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $248.8K | $237.4K | $264.7K | $293.4K | $297.8K | $298.7K | $277.4K | $312.0K |
| Goodwill | — | $914.0K | $914.0K | $914.0K | $914.0K | $914.0K | $914.0K | $914.0K |
| Intangible assets | $43.8K | $12.8M | $53.6K | $15.0M | $16.0M | $17.0M | $18.0M | $19.4M |
| Other non-current assets | $3.2M | $2.9M | $3.0M | $3.0M | $2.9M | $2.7M | $2.8M | $2.8M |
| Accounts payable | $19.6M | $16.5M | $18.6M | $13.8M | $13.4M | $13.9M | $13.9M | $12.1M |
| Accrued liabilities | $7.5M | — | $7.8M | — | — | — | $12.3M | — |
| Deferred revenue (current) | — | — | $25.0K | — | — | — | $207.1K | — |
| Short-term debt | — | — | $0 | — | — | — | $5.1M | — |
| Other current liabilities | $2.2M | $13.0M | $2.9M | $10.1M | $10.1M | $11.2M | $12.3M | $12.6M |
| Other non-current liabilities | $4.0M | $5.6M | $3.6M | $6.0M | $6.3M | $6.0M | $6.3M | $6.1M |
| Common stock & paid-in capital | — | — | — | — | — | — | — | — |
| Retained earnings | -$34.4M | -$30.1M | -$26.8M | -$25.4M | -$23.5M | -$22.7M | -$24.0M | -$22.1M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $168.7K | $387.0K | $3.0K | $187.2K | $843.8K | $3.9M | $1.9M | $475.5K |
| Investing cash flow | -$1.9M | -$61.2K | -$3.1M | -$690.8K | $285.9K | -$1.2M | -$26.8K | $189.6K |
| Financing cash flow | -$5.4M | -$763.3K | -$681.7K | -$386.9K | -$150.8K | -$5.5M | -$1.4M | -$536.8K |
| Free cash flow | $130.5K | $387.0K | $3.0K | $163.4K | $817.3K | $3.9M | $1.9M | $460.1K |
| Capital expenditures | $38.3K | $0 | -$1 | $23.8K | $26.5K | $47.6K | $2.3K | $15.4K |
| Depreciation & amortization | -$1.2M | $1.3M | $1.0M | $3.0M | -$953.8K | $1.0M | $1.5M | $1.1M |
| Share-based compensation | $77.9K | $106.8K | $172.2K | $81.3K | $80.7K | $74.2K | $74.8K | $76.4K |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | -$842.4K | -$2.7M | $6.5M | $113.7K | -$171.0K | -$1.2M | $390.8K | -$309.1K |
| Change in inventory | $703.9K | -$703.9K | $206.0K | -$2.3M | $865.7K | -$967.4K | -$1.3M | $170.9K |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Share repurchases | $0 | $61.0K | $0 | $10.4K | $7.2K | $245.9K | $98.4K | $98.8K |
| Debt issued | — | — | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $42.0M | $36.0M |
| Operating income | -$2.8M | -$6.4M | -$9.6M | -$5.7M | -$7.7M |
| Net income | -$2.8M | -$6.5M | -$6.3M | -$5.6M | -$3.5M |
| EPS (diluted) | $-0.19 | $-0.46 | $-0.44 | $-0.38 | $-0.24 |
| EPS (basic) | $-0.19 | $-0.46 | $-0.44 | $-0.38 | $-0.24 |
| Operating margin | — | — | — | -$14 | -$21 |
| Net margin | — | — | — | -$13 | -$10 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $76.8M | $75.6M | $81.8M | $92.9M | $84.5M |
| Total liabilities | $52.3M | $53.0M | $52.5M | $57.0M | $41.9M |
| Stockholders' equity | $24.9M | $22.9M | $29.6M | $36.3M | $42.8M |
| Total current assets | $37.1M | $36.5M | $35.7M | $45.9M | $45.7M |
| Total current liabilities | $36.7M | $31.6M | $28.0M | $28.6M | $19.3M |
| Cash & equivalents | $11.4M | $18.0M | $18.3M | $19.8M | $27.0M |
| Marketable securities (current) | — | — | — | — | — |
| Accounts receivable | $16.9M | $11.7M | $9.8M | $13.2M | $6.9M |
| Inventory | $6.2M | $4.0M | $4.6M | $9.9M | $8.4M |
| Other current assets | — | — | — | — | — |
| Property, plant & equipment | $264.7K | $277.4K | $367.9K | $284.0K | $442.6K |
| Goodwill | $914.0K | $914.0K | $914.0K | $914.0K | $882.0K |
| Intangible assets | $14.0M | $18.0M | $22.6M | $30.6M | $24.0M |
| Other non-current assets | $3.0M | $2.8M | $2.7M | $2.5M | $3.4M |
| Accounts payable | $18.6M | $13.9M | $14.0M | $10.8M | $9.6M |
| Accrued liabilities | $12.6M | $12.3M | $13.6M | $17.6M | $8.7M |
| Deferred revenue (current) | $25.0K | $207.1K | $220.4K | $614.6K | $0 |
| Short-term debt | $0 | $5.1M | $0 | — | — |
| Other current liabilities | $12.6M | $12.3M | $13.6M | $17.6M | $943.0K |
| Other non-current liabilities | $5.8M | $6.3M | $6.5M | $7.6M | $7.5M |
| Common stock & paid-in capital | — | — | — | — | — |
| Retained earnings | -$26.8M | -$24.0M | -$17.5M | -$11.2M | -$5.6M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $4.9M | -$612.2K | $6.1M | $8.5M | $6.3M |
| Investing cash flow | -$4.7M | $57.8K | -$105.7K | -$13.7M | -$501.9K |
| Financing cash flow | -$6.7M | $196.9K | -$7.4M | -$2.1M | -$3.6M |
| Free cash flow | $4.8M | -$678.6K | $5.8M | $8.4M | $6.2M |
| Capital expenditures | $97.9K | $66.5K | $281.3K | $102.1K | $103.5K |
| Depreciation & amortization | $4.1M | $4.9M | $4.9M | $5.3M | $4.6M |
| Share-based compensation | $408.3K | $301.9K | $365.0K | $447.5K | $741.9K |
| Deferred income taxes | — | — | — | $0 | $0 |
| Change in accounts receivable | $5.2M | $1.9M | -$3.4M | $6.1M | -$5.5M |
| Change in inventory | -$2.2M | -$2.4M | $23.1K | -$911.1K | -$4.8M |
| Share repurchases | $263.5K | $579.0K | $740.5K | $1.1M | $1.4M |
| Debt issued | — | — | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CPIX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-18 to 2026-03-18
Recent transactions
- Most recent: Brown Martin S JR (Director) — Grant / award of 1,800 shares on 2026-03-18.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Brown Martin S JR | Director | Grant / award | 2026-03-18 | 1,800 |
| Galante Joseph C | Director | Grant / award | 2026-03-18 | 1,800 |
| Jones James | Director | Grant / award | 2026-03-18 | 1,800 |
| Krogulski Kenneth | Director | Grant / award | 2026-03-18 | 1,800 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-03-18 | Brown Martin S JR | Director | Grant / award | 1,800 | $2.80 |
| 2026-03-18 | Galante Joseph C | Director | Grant / award | 1,800 | $2.80 |
| 2026-03-18 | Jones James | Director | Grant / award | 1,800 | $2.80 |
| 2026-03-18 | Krogulski Kenneth | Director | Grant / award | 1,800 | $2.80 |
| 2026-03-18 | Krogulski Kenneth | Director | Grant / award | 4,000 | $2.80 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:55 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-28 | 8-K | 2026-08-28 | View on SEC.gov → |
| 2026-08-07 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-04 | 8-K | 2026-08-04 | View on SEC.gov → |
| 2026-07-13 | 8-K | 2026-07-13 | View on SEC.gov → |
| 2026-07-01 | 8-K | 2026-06-29 | View on SEC.gov → |
| 2026-06-25 | 8-K | 2026-06-24 | View on SEC.gov → |
| 2026-05-08 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-05 | 8-K | 2026-05-05 | View on SEC.gov → |
| 2026-04-24 | 8-K | 2026-04-21 | View on SEC.gov → |
| 2026-04-23 | 8-K | 2026-04-22 | View on SEC.gov → |
| 2026-03-20 | 4 | 2026-03-18 | View on SEC.gov → |
| 2026-03-20 | 4 | 2026-03-18 | View on SEC.gov → |
Recent news
Headlines about CPIX (Cumberland Pharmaceuticals Inc.). Links open the publisher — we don’t host full articles.
-
CUMBERLAND PHARMACEUTICALS ANNOUNCES NATIONAL CALL TO PRESENT AN UPDATE ON ITS IFETROBAN DMD PROGRAM
Yahoo Finance · 2026-10-19 -
Liquidity Mapping Around (CPIX) Price Events
Stock Traders Daily · 2026-10-18 -
Cumberland Pharmaceuticals: Pivot Into Drug Development Creates Risk, Opportunity
Seeking Alpha · 2026-08-13 -
Cumberland Pharmaceuticals Inc (CPIX) (Q2 2026) Earnings Call Highlights: Strategic ...
Yahoo Finance · 2026-08-05 -
Cumberland outlines over 5 years of runway following $1.50 per share special dividend
Seeking Alpha · 2026-08-04 -
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2026 Earnings Call Transcript
Seeking Alpha · 2026-08-04 -
Cumberland Pharmaceuticals Q2 Earnings Call Highlights
Yahoo Finance · 2026-08-04 -
CUMBERLAND PHARMACEUTICALS REPORTS COMPANY UPDATE & Q2 2026 FINANCIAL RESULTS
Yahoo Finance · 2026-08-04
No headlines in this category right now — try “All”.